Ovarian Cancer

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

By

It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.

Ovarian Cancer Vaccine Shows Promise

Ovarian Cancer Vaccine Shows Promise

The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

Highly Selective, First-in-Class CDK4 Inhibitor Promising in Ovarian Cancer

By

Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma

By

Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.

Antidepressants May Not Increase Ovarian Cancer Risk

Antidepressants May Not Increase Ovarian Cancer Risk

Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.

Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients

Ovarian cancer has high rates of mortality as it is often diagnosed in late stages with spread to the peritoneal surface.

Normal tissue BRCA1 methylation associated with risk for high-grade ovarian cancer

Females with BRCA1 mutations in their germline have a high risk of HGSOC.

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

Survival Predictors in Ovarian Cancer and Current Immunotherapeutic Strategies

By

Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

Current and Future Roles of PARP Inhibitors in Ovarian Cancer

By

Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.

Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy

Rucaparib May Prolong PFS in Ovarian Cancer Responsive to Platinum Chemotherapy

By

Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer

By

First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).

Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse

Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse

By

Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.

Additional FDA Approval for Olaparib Tablets in Ovarian Cancer

Additional FDA Approval for Olaparib Tablets in Ovarian Cancer

By

Patients in the olaparib arm experienced a 70% reduction in the risk of disease progression or death vs placebo.

Olaparib Tablets Prolong Progression-free Survival in Ovarian Cancer

Olaparib Tablets Prolong Progression-free Survival in Ovarian Cancer

By

Maintenance treatment with olaparib tablets may prolong PFS without negatively affecting quality of life among patients with relapsed ovarian cancer.

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

By

Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.

Durvalumab Plus Olaparib or Cediranib Active and Tolerable in Female Cancers

Durvalumab Plus Olaparib or Cediranib Active and Tolerable in Female Cancers

By

Durvalumab plus olaparib or intermittent cediranib is clinically active and tolerable in treating female cancers.

Varlilumab Active and Well-tolerated in Solid Tumors

Varlilumab Active and Well-tolerated in Solid Tumors

By

This anti-CD27 antibody demonstrated clinical activity among and was well-tolerated by patients with solid tumors including melanoma, prostate cancer, and renal cell carcinoma.

Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors

Phase 1 Trial of Palbociclib With Chemotherapy for Solid Tumors

By

Safety, tolerability, and efficacy of palbociclib in combination with cisplatin or carboplatin among patients with advanced/metastatic solid tumors.

Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer

Adding Bevacizumab to Chemo May Prolong Survival in Recurrent Ovarian Cancer

By

Adding bevacizumab to platinum-based chemotherapy may improve survival among women with recurrent ovarian cancer.

Inferior End of Life Care for Ethnic-Minority Patients With Ovarian Cancer

Inferior End of Life Care for Ethnic-Minority Patients With Ovarian Cancer

By

Study findings show that "important disparities in use of end-of-life care persist among racial and ethnic minorities."

Niraparib Approved for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Niraparib Approved for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

By

Approval was based on findings from the phase 3 NOVA trial, the results of which were published in The New England Journal of Medicine.

Ovarian Cancer Treatment Regimens

Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

By

Combined liquid-based Pap and CT-DNA may be a new method for tumor-derived driver mutation screening in primary ovarian carcinoma.

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

By

Patients with newly diagnosed ovarian cancer rank nausea as the most concerning side effect associated with chemotherapy.

Elderly Patients and Treatment Tolerance in Phase 1 Trials

Elderly Patients and Treatment Tolerance in Phase 1 Trials

By

Study results suggest that carefully selected elderly patients with recurrent or refractory gynecologic malignancy should be enrolled in phase 1 trials.

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

Hypermethylation of DNA Repair Genes in Ovarian Carcinoma

By

Hypermethylation of HRR-associated genes was not associated with improved survival in ovarian cancer.

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

By

Adjuvant platinum-based chemotherapy did not improve survival in women with low-grade serous ovarian cancer.

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

By

BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.

Hospital Readmission Reduction Program May Unfairly Penalize Hospitals

Hospital Readmission Reduction Program May Unfairly Penalize Hospitals

By

The Hospital Readmission Reduction Program may unfairly penalize hospitals if 30-day readmission rates are the only metric for care quality.

Burnout and Productivity Loss Among Gynecologic Oncologists

Burnout and Productivity Loss Among Gynecologic Oncologists

By

Gynecologic oncologists are at a particularly high risk for burnout compared with other specialties, suggesting a need for burnout prevention and wellness programs.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs